Asia
Chinese Drug Regulator Accepts Zhifei Biological Products' Application for RSV Vaccine Trial
China's National Medical Products Administration accepted Chongqing Zhifei Biological Products' (SHE:300122) application for the clinical trial of a vaccine against respiratory syncytial virus, according to a Shenzhen bourse filing on Monday.The trial will be for the recombinant respiratory syncytial virus vaccine for intranasal administration (chimpanzee adenovirus vector).
SHE:300122
